KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Receivables - Net: 2014-2024

Historic Receivables - Net for Travere Therapeutics (TVTX) over the last 11 years, with Dec 2024 value amounting to $27.1 million.

  • Travere Therapeutics' Receivables - Net rose 229.37% to $83.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.0 million, marking a year-over-year increase of 229.37%. This contributed to the annual value of $27.1 million for FY2024, which is 28.03% up from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Receivables - Net is $27.1 million, which was up 28.03% from $21.2 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Receivables - Net ranged from a high of $27.1 million in FY2024 and a low of $15.9 million during FY2021.
  • Moreover, its 3-year median value for Receivables - Net was $21.2 million (2023), whereas its average is $21.6 million.
  • As far as peak fluctuations go, Travere Therapeutics' Receivables - Net decreased by 11.76% in 2020, and later grew by 28.03% in 2024.
  • Over the past 5 years, Travere Therapeutics' Receivables - Net (Yearly) stood at $15.9 million in 2020, then declined by 0.07% to $15.9 million in 2021, then grew by 4.60% to $16.6 million in 2022, then increased by 27.23% to $21.2 million in 2023, then climbed by 28.03% to $27.1 million in 2024.